GH Research PLC

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gemini Therapeutics

Janux Therapeutics

Omega Flex

Polar Power

Red Violet

Via Renewables

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?

Atai Life Sciences BV

COMPASS Pathways

Cybin

Ameri Holdings

Mind Medicine MindMed

Advisorshares Psychedelics ETF

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

7 Psychedelics Stocks to Buy for a Big Drug Boom

The mean of analysts' price targets for GH Research PLC (GHRS) points to a 205.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gave updates on its business.

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business.

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

The stock price of GH Research PLC (NASDAQ: GHRS) increased by 21.86% today. This is why it happened.

GH Research Stock (GHRS): Why The Price Jumped Today

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffering from treatment-resistant depression (TRD). The Ireland-based company, which this year announced a capital raise of $315 million, is focused exclusively on research around the psychoactive molecule 5-MeO-DMT to treat depression, a condition that affects many millions of people around the world.

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial met its primary endpoint with 7 of 8 patients (87.5%) in remission at day 7 after dosing.

GH Research Posts Data From Treatment-Resistant Depression Trial

Field Trip Health Ltd

Jaguar Health

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business.

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021.

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June.

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

Elevation Oncology

Graphite Bio

Mister Car Wash

Alpha Teknova

Acurx Pharmaceuticals LLC

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

7 Companies Go Public Today. What Investors Need to Know.

GH Research has filed proposed terms for a $125 million U.S. IPO. The firm is developing treatments for treatment resistant depression and other neurological conditions.

GH Research Seeks $125 Million IPO

News for GH Research PLC Stock (GHRS)